$901 Million is the total value of GREAT POINT PARTNERS LLC's 31 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | Buy | PTC THERAPEUTICS, INC. | $88,847,000,000 | +130004.4% | 1,974,385 | +8.8% | 9.86% | +45.9% |
| ZGNX | Buy | ZOGENIX, INC. | $76,132,000,000 | +115274.2% | 1,593,396 | +32.8% | 8.45% | +29.4% |
| BOLD | Buy | AUDENTES THERAPEUTICS, INC. | $72,802,000,000 | +118539.6% | 1,922,937 | +22.3% | 8.08% | +33.1% |
| KURA | Buy | KURA ONCOLOGY, INC. | $60,011,000,000 | +136655.4% | 3,047,800 | +15.2% | 6.66% | +53.4% |
| XLRN | Buy | ACCELERON PHARMA INC | $59,537,000,000 | +118261.5% | 1,449,300 | +34.2% | 6.61% | +32.7% |
| ASND | Buy | ASCENDIS PHARMA ASsposored adr | $57,575,000,000 | +117770.4% | 500,000 | +20.5% | 6.39% | +32.2% |
| TCDA | New | TRICIDA, INC. | $56,191,000,000 | – | 1,423,998 | +100.0% | 6.24% | – |
| MRTX | New | MIRATI THERAPEUTICS INC.put | $30,900,000,000 | – | 300,000 | +100.0% | 3.43% | – |
| MRTX | New | MIRATI THERAPEUTICS INC. | $30,900,000,000 | – | 300,000 | +100.0% | 3.43% | – |
| ZYME | Buy | ZYMEWORKS INC. | $23,409,000,000 | +9918967.8% | 1,064,041 | +7183.0% | 2.60% | +11200.0% |
| RTRX | New | RETROPHIN INC. | $20,162,000,000 | – | 1,003,600 | +100.0% | 2.24% | – |
| MRTX | New | MIRATII THERAPEUTICS INC.call | $18,025,000,000 | – | 175,000 | +100.0% | 2.00% | – |
| PRTA | New | PROTHENA CORPORATION PLC | $17,718,000,000 | – | 1,676,250 | +100.0% | 1.97% | – |
| BHVN | New | BIOHAVEN PHARMACEUTICAL HOLDING CO LTD. | $15,327,000,000 | – | 350,000 | +100.0% | 1.70% | – |
| DERM | Buy | DERMIRA INC. | $14,846,000,000 | +72943.1% | 1,552,900 | +3.5% | 1.65% | -18.1% |
| ZGNX | New | ZOGENIX, INC.put | $14,334,000,000 | – | 300,000 | +100.0% | 1.59% | – |
| IOVA | New | IOVANCE BIOTHERAPETUICS, INC.call | $4,904,000,000 | – | 200,000 | +100.0% | 0.54% | – |
| MNTA | Buy | MOMENTA PHARMACEUTICALS, INC. | $4,259,000,000 | +94586.5% | 342,064 | +10.5% | 0.47% | +6.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.